Caris Life Sciences, Inc.
CAI
$38.27
-$0.215-0.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | 181.40M | 120.92M | 100.05M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 181.40M | 120.92M | 100.05M | ||
| Cost of Revenue | 67.71M | 63.85M | 62.50M | ||
| Gross Profit | 113.69M | 57.06M | 37.55M | ||
| SG&A Expenses | 106.63M | 91.95M | 79.78M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 199.39M | 178.87M | 167.06M | ||
| Operating Income | -17.99M | -57.95M | -67.01M | ||
| Income Before Tax | -71.79M | -102.58M | -66.19M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -71.79M | -102.58M | -66.19M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -71.79M | -102.58M | -66.19M | ||
| EBIT | -17.99M | -57.95M | -67.01M | ||
| EBITDA | -11.58M | -50.91M | -55.40M | ||
| EPS Basic | -7.97 | -3.57 | -2.54 | ||
| Normalized Basic EPS | -0.52 | -1.80 | -1.17 | ||
| EPS Diluted | -7.97 | -3.57 | -2.54 | ||
| Normalized Diluted EPS | -0.52 | -1.80 | -1.17 | ||
| Average Basic Shares Outstanding | 64.92M | 35.62M | 35.37M | ||
| Average Diluted Shares Outstanding | 64.92M | 35.62M | 35.37M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||